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Summary HuIL-6 cDNA, cloned into a neomycin resistant conferring expression vector, BMGNeo, was
transfected into Lewis Lung Carcinoma (LLC) cells. LLC cells (5 x 106 ml-X) transfected with IL-6 cDNA
(LLC-IL6) secreted IL-6 into the culture supernatant at a concentration of 9.9 ngml-' within 48 h. When
1,000,000 of untransfected LLC, BMGNeo vector transfected LLC (LLC-Neo) or LLC-1L6 cells were
transplanted into C57BL/6 mice subcutaneously, the mean ± s.d. of survival times of these mice were
33.3 ± 9.7, 34.3 ± 7.1 and 17.0 ± 3.1 days, respectively. The survival time of LLC-1L6 cells transplanted mice
was significantly shorter than that of LLC (P<0.01) or LLC-Neo (P<0.01) cells transplanted mice without a
measurable difference of tumour size. Plasma concentration of IL-6 steadily increased in LLC-IL6 transplanted
mice. Body weight and serum albumin were significantly lower in LLC-1L6 transplanted mice than in LLC
transplanted mice. Mouse IL-la and mouse TNF-a were not detected in the plasma of LLC-1L6 transplanted
mice. These data suggested that secretion of IL-6 from LLC cells was unable to alter net tumour growth rate
but rather caused a state similar to cachexia without detectable increase of IL-Ia and TNF-a in the plasma.
This state may be responsible for the shortened survival of LLC-1L6 tumour-bearing mice.
IL-6 is multifunctional cytokine which was originally
identified as a B cell differentiation factor, B-cell stimulatory
factor 2 (BSF-2) (Hirano et al., 1986; Snick, 1990). This
molecule, which is produced by many different cells, is also
known as IFN-P2, hybridoma/plasmacytoma growth factor
(HPGF), plasmacytoma growth factor (PCT-GF), hepato-
cyte-stimulating factor (HSF), 26-kDa protein and cytotoxic
T-cell differentiation factor (CDF) (Snick, 1990). IL-6 can act
as a cytotoxic T cell differentiation factor as well as a
stimulatory factor for T and B cells and enhances the
cytotoxic activity of NK cells via IL-2 (Luger et al., 1989).
IL-6 acts predominantly by enhancing IL-2 responsiveness
whereas IL-1 acts predominantly on IL-2 production (Snick,
1990). Indeed an anti-tumour effect of human recombinant
IL-6 in mice bearing syngenic tumour has been reported
(Mule et al., 1990; Kitahara et al., 1990). Thus, IL-6 is
considered to be one of the important factors for the rejec-
tion of cancer cells and the development of immunotherapy
for cancer patients.
The local secretion of cytokine from tumour cells may
more effectively induce an immune response against cancer
cells than systemic administration because of higher and
stable concentration at the tumour site. Indeed it has been
reported that an effective immune response can be induced in
syngenic mice by the transplantation of cytokine producing
tumours transfected with cDNAs coding for cytokines such
as IL-2, IL-4, IL-7, P-, y-IFN, tumour necrosis factor (TNF)-
a and granulocyte colony-stimulating factor (G-CSF) (Miz-
uno et al., 1990; Gansbacher et al., 1990; Teng et al., 1991;
Asher et al., 1991; Blankenstein et al., 1991; Colombo et al.,
1991). However, the induction of an immune response by the
tumour cells transfected with IL-6 cDNA is still controversial
(Blankenstein et al., 1991; Okada, 1990). Thus, in order to
examine the effect of IL-6 cDNA transfection to tumour cells
we have transfected human IL-6 cDNA into a spontaneous
murine lung cancer, Lewis Lung Carcinoma (LLC) cells
(Sugiura & Stock, 1955; Merriman et al., 1989) and tested its
effect on potential tumour rejection.
Materials and methods
Mice
Inbred 5-week-old female C57BL/6 mice were obtained from
Japan Charles River Co., Ltd. (Atsugi, Japan). These were
maintained under specific-pathogen-free conditions in our
laboratory.
Cell lines and culture
LLC cells originated as a spontaneous carcinoma of the lung
in a C57BL/6 mouse (Sugiura et al., 1955; Merriman et al.,
1989). LLC cells and transfected LLC cells were cultured in
Iscove medium (IBL, Fujioka, Japan) with 20% FCS (IBL,
Fujioka, Japan).
Transplantation oftumour cells and observation oftumour
bearing mice
Tumour cells were harvested during exponential growth of
the cell culture. Cell viability was determined by trypan blue
dye exclusion. Cells were washed twice in Hanks balanced
salt solution (IBL, Fujioka, Japan) and 1 x 106 cells were
transplanted subcutaneously into the flank of C57BL/6 mice.
Body weight was measured twice a week. Food and water
intakes were observed every day and twice a week, respec-
tively.
Expression vectorfor the transfection ofIL-6 cDNA
The eukaryotic cDNA expression vector BMGNeo, conferr-
ing also neomycin resistance, was kindly supplied from Dr
Fritz Melchers, Basel Institute for Immunology (Karasuyama
& Melchers, 1988). Full length human IL-6 cDNA was
obtained from American Type Culture Collection and intro-
duced into the Sal I site of BMGNeo using polymerase chain
reaction supported protocols. Briefly, human IL-6 cDNA was
amplified with Sal I site containing up and down primers
using polymerase chain reaction under standard conditions.
After the reaction with Sal I DNA methylation enzymes the
amplified human IL-6 cDNA was introduced into Sal I site
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of BMGNeo using T4 DNA ligase (BOEHRINGER MAN-
NHEIM in USA).
Transfections
BMGNeo and HuIL-6 cDNA containing BMGNeo, BMG-
Neo-IL6 were transfected into LLC cells using the Lipofectin
reagent (GIBCO BRL, MD USA) according to the manufac-
turers' instructions (Felgner et al., 1987). 5 x 106 of LLC cells
were plated in a 60 mm tissue culture dish (FALCON 3002)
in 5 ml Iscove with 20% FCS and cultured overnight. Ten .g
ofplasmid DNA was used for transfection. Prior to transfec-
tion cells were washed twice with 3 ml of Opti-MEM I
(GIBCO, NY USA) and then Lipofectin DNA complex was
added. Cells were incubated for 8 h at 37°C in a humidified
atmosphere, following which 3 ml of medium with 20% FCS
was added. After an additional 48 h incubation 1 mgml-' of
G418 (SIGMA, MO USA) was added. Cells resistant to
neomycin were selected and used for this study without
further cloning. IL-6 containing supernatants were prepared
by culturing 5 x 106 ml-' LLC-IL6 for 48 h and testing for
IL-6 protein by ELISA.
Cytokine assay
Human IL-6 and mouse IL-la( protein determinations were
made using an ELISA kit, InterTest-6TM and InterTest-
lXXTM purchased from Genzyme, Boston USA, respectively.
Mouse TNF-o protein determinations were made using an
mouse TNF-x ELISA kit purchased from ENDOGEN, Bos-
ton USA.
Biochemical analysis ofthe serum
Total protein, albumin, blood urea nitrogen, creatinine,
triglyceride, total cholesterol, free fatty acid, cholinesterase,
calcium and phosphate were assayed using an automatic
analyser (HITACHI, model 736).
Monoclonal antibody
Anti-human IL-6 mAb, SK2 was established as previously
described (Galfre et al., 1977). Eight-week-old female BALB/
c mice were immunised with 10jg of recombinant human
IL-6 at day 1, 14, 22 and 28. Hybridomas of spleen cell and
the murine myeloma cell line, P3UI, were established using
polyethylene glycol. An anti-human IL-6 mAb producing
clone was isolated and injected into mice intraperitoneally for
ascites production. Purified IgG was obtained from the
ascites using a protein A agarose column. 0.41 lgg ml-' of
anti-human IL-6 mAb, SK2 could neutralise 1 ng ml-' of
IL-6.
Macroscopical andpathological examination
All the organs of dissected animals were macroscopically
examined and histological examinations were done for liver,
spleen, lung, heart and kidney 14 days after transplantation.
Statistical analysis
The data of body weight and serum albumin were analysed
for significance by the two-tailed t-test. The survival curve of
each group was analysed by log rank test. P values were
calculated by comparison of experimental groups.
Results
Characteristics oftransfected LLC
BMGNeo and BMGNeo-IL6 were transfected into LLC cells
using lipofectin and successful transfectants were selected in
1 mg ml-' of G418 containing medium. Doubling times of
LLC, BMGNeo transfected LLC (LLC-Neo) and BMGNeo-
IL6 transfected LLC (LLC-IL6) cells were 20.4, 20.6 and
23.2 h, respectively. The morphology of transfected LLC cells
was identical to that of non transfected LLC cells both in
vitro and in vivo. Cells were cultured for 48 h at 5 x 106 cells
ml-' to produce supernatants which were used for assaying
IL-6 content. The supernatant of LLC-IL6 cells contained
9.9 ngml-' of IL-6, whereas no IL-6 was detected in the
supernatants of LLC and LLC-Neo cells.
Tumour growth in C57BL/6 mice
In vivo tumour growth curves as measured by tumour size of
LLC, LLC-Neo and LLC-IL6 cells are shown in Figure 1.
Tumour size was calculated as the mean of the longest
tumour length and width after 1 x 106 LLC, LLC-Neo or
LLC-IL6 cells had been transplanted subcutaneously into the
flank of C57BL/6 mice. Each group consisted of three mice.
Tumour nodule was palpable 10 days after transplantation of
the tumour cells in C57BL/6 mice. The growth rate of LLC-
IL6 and LLC-Neo cells was similar to that of LLC cells
(Figure 1).
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Figure 1 In vivo tumour growth of LLC, LLC-Neo, LLC-IL6 in
C57BL/6 mice. 1 x 106 LLC, LLC-Neo or LLC-IL6 cells were
transplanted into the flank of C57BL/6 mice. Tumour size was
measured as the mean of the longest length and width.
Each group consisted of three mice. ( O ), LLC;
(A ), LLC-Neo; ( 0 ), LLC-IL6.
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Figure 2 Survival curves of LLc, LLC-Neo or LLC-IL6 trans-
planted mice. 1 x 106 cells were transplanted into the flank of
C57BL/6 mice. Each group consisted of six mice. ( 0 ),
LLC transplanted mice; ( A ), LLC-Neo transplanted
mice; ( * ), LLC-IL6 transplanted mice. The mean ±
s.d. of survival times of LLC, LLC-Neo and LLC-IL6 cells
transplanted mice were 33.3 + 9.7, 34.3 ± 7.1 and 17.0 ± 3.1 days,
respectively. Survival time of LLC-IL6 transplanted mice was
significantly shorter than that of LLC (P<0.01) or LLC-Neo
(P<0.01) transplanted mice.INDUCTION OF A STATE SIMILAR TO CACHEXIA BY IL-6 TRANSFECTED TUMOUR 941
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Figure 3 a, Body weight of LLC or LLC-IL6 transplanted mice. 1 x 106 cells were transplanted into the flank of C57BL/6 mice.
Each group consisted of six mice. ( O ), LLC transplanted mice; ( ), LLC-IL6 transplanted mice. Body weight
of LLC-IL6 transplanted mice were significantly lower than those of LLC transplanted mice at 21 (P<0.05) days after the
transplantation. b, Food intake of LLC, LLC-Neo or LLC-IL6 transplanted mice. 1 x 106 cells were transplanted into the flank of
C57BL/6 mice. Each group consisted of six mice. ( O ), LLC transplanted mice; ( A ), LLC-Neo transplanted
mice; ( ), LLC-IL6 transplanted mice. c, Water intake of LLC, LLC-Neo or LLC-IL6 transplanted mice. I x 106 cells
were transplanted into the flank of C57BL/6 mice. Each group consisted of six mice. ( O ), LLC transplanted mice;
(A ), LLC-Neo transplanted mice; ( * ), LLC-IL6 transplanted mice.
Survival time of tumour transplanted C57BL/6 mice
Groups of six mice each were transplanted with LLC, LLC-
Neo or LLC-IL6 cells and the survival time was determined.
The mean ± s.d. of survival times of LLC, LLC-Neo and
LLC-IL6 cells transplanted mice were 33.3 ± 9.7, 34.3 + 7.1
and 17.0 ± 3.1 days, respectively (Figure 2). Survival time of
LLC-IL6 transplanted mice was significantly shorter than
that of LLC (P<0.01) or LLC-Neo (P<0.01) transplanted
mice. Similar results were observed in the experiments using
intraperitoneal injection of transfected or untransfected LLC
cells (data not shown).
Body weight andfood and water intake ofLLC or LLC-IL6
transplanted mice
The mean ± s.d. of body weight of LLC or LLC-IL6 trans-
planted mice is shown in Figure 3a. Each group consisted of
six mice. Body weight of LLC-IL6 transplanted mice did not
increase while that of LLC transplanted mice increased
steadily during the observation period. Body weight of LLC-
IL6 transplanted mice was significantly lower than that of
LLC transplanted mice at 21 (P<0.05) days after the trans-
plantation. Food and water intakes were decreased in LLC-
IL6 transplanted mice about 10 days after transplantation.
Biochemical analysis ofthe serumfrom LLC or LLC-IL6
transplanted mice
1 x 106 LLC or LLC-IL6 cells were transplanted to two
groups of C57BL/6 mice. The serum was sampled from three
mice each at 10 and 14 days after the transplantation. The
serum level of albumin in LLC-IL6 transplanted mice was
significantly decreased in comparison to that of non-trans-
planted mice at 10 (P<0.001) or 14 (P<0.001) days after
the transplantation. In contrast LLC transplanted mice had
normal albumin levels. The serum level of albumin of LLC-
IL6 transplanted mice thus also was significantly lower than
that of LLC transplanted mice at 10 (P<0.05) and 14
(P< 0.01) days after the transplantation (Figure 4). No other
consistent change was observed in total protein, blood urea
nitrogen, creatinine, triglyceride, total cholesterol, free fatty
acid, cholinesterase, calcium and phosphate in the serum of
LLC or LLC-IL6 transplanted mice.
Plasma concentration ofhuman IL-6, mouse IL-Jla and mouse
TNF-am
The plasma concentrations of human IL-6, mouse IL-lot and
mouse TNF-a were measured by ELISA at 10 and 14 days
after the transplantation. The values were obtained from
three mice. In LLC transplanted or non-transplanted, normal
mice, human IL-6 was not detected in the plasma. In con-
trast, mean ± s.d. of plasma concentrations of human IL-6
were 3.46 ± 0.47 and 4.03 ± 0.70 at 10 or 14 days after the
transplantation, respectively. Mouse IL-la and mouse TNF-x
in the plasma were below the detection limit in both LLC
and LLC-IL6 transplanted mice.
Effect ofanti-human IL-6 mAb on the survival ofLLC-IL6
transplanted mice
We next examined the effect of anti-human IL-6 mAb to
clarify whether secreted IL-6 shortened the survival of LLC-
IL6 transplanted mice. One hundred iLg of anti-human IL-6
mAb, SK2 was injected subcutaneously twice a week after
the transplantation of 1 x 106 LLC-IL6 cells into the flank of
C57BL/6 mice. Each group consisted of six mice. In this
experiment the mean ± s.d. of the survival of LLC-IL6 trans-
planted mice was 22.6 ± 4.5 days. Although this seems to be
slightly longer than that of the survival of IL-6 transplanted
mice of Figure 2, the in vivo growth of the tumour depend on
the condition of the transplanted cells. The injection of anti-
human IL-6 mAb prolonged the survival of LLC-IL6 trans-
planted mice to 32.1 ± 2.2 days (P<0.001) (Figure 5). This
survival time is identical to that of untransfected LLC trans-
planted mice, which was 33.3 9.7 days (Figure 2).
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Figure 4 Serum albumin of LLC or LLC-IL6 transplanted mice.
1 x 106 cells were transplanted into the flank of C57BL/6 mice.
Each value is the mean from three mice. (0), LLC transplanted
mice; (U), LLC-IL6 transplanted mice; (U), normal mice. The
serum level of albumin in LLC-IL6 transplanted mice was
significantly decreased in comparison to that of non-transplanted
mice at 10 (P<0.001) or 14 (P<0.001) days after the transplan-
tation whereas that in LLC transplanted mice was not significantly
decreased. The serum level of albumin in LLC-IL6 transplanted
mice was significantly lower than that in LLC transplanted mice
at 10 (P<0.05) and 14 (P<0.01) days after the transplantation.
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Macroscopical and histological examination
The organs ofdissected mice were macroscopically examined.
Spleen weights of LLC and LLC-IL6 transplanted mice were
0.081 ± 0.047 and 0.197 ± 0.048 (P<0.05), respectively. His-
tologically, numerous megakaryocytes were observed in the
spleen of IL-6 transplanted mice (Figure 6b). No patho-
logical change was observed in other organs such as liver,
lung, heart and kidney.
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Figure 5 Effect of anti-human IL-6 mAb on the survival of
LLC-IL6 transplanted mice. Each group consisted of six
mice. ( ), LLC-IL6 transplanted mice without mAb,
( 0 ), 100 pg of anti-human IL-6 mAb, SK2 was injected
subcutaneously twice a week after the transplantation of 1 x 106
LLC-IL6. Mean ± s.d. of the survival of LLC-IL6 transplanted
mice was 22.6 ± 4.5 days. The injection of anti-human IL-6 mAb
prolonged the survival of LLC-IL6 transplanted mice to 32.1 ±
2.2 days (P<0.001).
IL-6 has many functions that may be of potential benefit for
patients such as anti-tumour effect and stimulation of throm-
bopoiesis (Mule et al., 1990; Kitahara et al., 1990; Hill et al.,
1990). However, other functions of IL-6 such as growth
stimulation of myeloma, development of glomerulonephritis,
induction of hypercalcaemia, inhibition of albumin synthesis
may have adverse effect for patients (Bataille et al., 1989;
Suematsu et al., 1989; Andus et al., 1987; Black et al., 1991).
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Figure 6 Pathological analysis of spleens in LLC a, and LLC-IL6 b, transplanted mouse 14 days after tumour inoculation.
Numerous megakaryocytes are observed in spleen of LLC-IL6 transplanted mice.
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Thus, clinical benefit of IL-6 is controversial. We have trans-
fected IL-6 cDNA to LLC cells in the expectation to see an
anti-tumour effects as reported (Mule et al., 1990; Kitahara
et al., 1990). Unexpectedly, IL-6 cDNA transfection to LLC
cells could not alter net tumour growth rate but caused a
state similar to cachexia in tumour bearing mice.
Body weight loss is commonly observed in patients with
cancer and is associated with other symptoms such as
anorexia, nausea, asthenia, muscle weakness and anaemia
('cancer associated cachexia') (Oliff et al., 1987; Lonnroth et
al., 1990; Gelin et al., 1991). Secretion ofTNF and IL-1 from
tumour cells has been reported to induce cachexia to tumour
bearing mice (Oliff et al., 1987; Lonnroth et al., 1990; Gelin
et al., 1991). In a more recent report, secretion of IL-6 from
Chinese hamster ovarian cells cause cachexia, hypercalcae-
mia, leukocytosis and thrombocytosis in tumour-bearing
nude mice (Black et al., 1991). In the present study, the
survival of LLC-IL6 transplanted mice was significantly
shorter than that of LLC transplanted mice without an
observable difference of tumour growth and metastasis to
organs such as liver, lung and lymphnode (data not shown).
In addition, body weight and serum albumin were
significantly lower in LLC-IL6 transplanted mice. Food and
water intakes were also decreased in the group. Mouse IL-la
and mouse TNF-a were not detected in the plasma of LLC-
IL6 transplanted mice. Moreover, the injection of anti-IL6
mAb prolonged the survival of LLC-IL6 transplanted mice.
These data suggested that LLC-IL6 transplanted mice died
earlier from a state similar to cachexia induced by IL-6 itself.
The effect of IL-6 cDNA transfection to tumour cells on
the survival is controversial. Okada et al. reported that IL-6
cDNA transfected RLY8, thymoma cell, induced a CD8+ T
cells dependent immune response (Okada, 1990). In contrast,
Blankenstein et al. could not induce an immune response to
IL-6 cDNA transfected J558L, myeloma cells (Blankenstein
et al., 1991). They also observed acceleration of tumour
growth by IL-6 cDNA transfection which may act as an
autocrine growth factor of myeloma (Blankenstein et al.,
1991). In the present study, transfection of IL-6 cDNA to
tumour cells induced a state similar to cachexia and hypo-
albuminemia in tumour bearing mice. We speculate that IL-6
acts to enhance T cell mediated cytotoxicity when a tumour
is immunogenic in the transplanted host. Under these cir-
cumstances IL-6 producing tumour cells might be rejected by
augmentation ofa T cell killing without severe complications.
Conversely huge amount of IL-6 is produced by established
tumour cells and cause a state similar to cachexia to the mice
when IL-6 producing tumour cells fail to be rejected. It is still
unknown whether IL-6 directly induce hypoalbuminemia as
has been reported in in vitro studies or whether a state
similar to cachexia caused hypoalbuminemia secondly
(Andus et al., 1987). In LLC-IL6 transplanted mice,
splenomegary was observed and many megakaryocytes were
seen in the spleen without attended thrombocytosis. No
pathological change was observed in liver, lung, heart and
kidney, including absence of glomerulonephritis (data not
shown). It is considered that several functions of IL-6 might
become dominant depending on the tumour cells secreting
IL-6. Thus, the clinical application of IL-6 for patients with
cancer will need carefulness for adverse effects, including a
state similar to cachexia.
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